n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, September 18th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Pivot Pharmaceuticals, Inc. (PVOTF)

OTC Markets and MarketWatch reported on Pivot Pharmaceuticals, Inc. (PVOTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pivot Pharmaceuticals, Inc. is developing novel treatments to address unmet medical needs. The Company's pipeline targets indications such as cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology, and eye disease. An emerging biopharmaceutical enterprise, Pivot Pharmaceuticals is headquartered in Vancouver, British Columbia. Its wholly-owned subsidiary is Pivot Green Stream, Inc. Pivot Pharmaceuticals' shares trade on the OTC Markets Group's OTCQB.

Pivot Pharmaceuticals engages in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals and also drug delivery platform technologies. It concentrates on the pharmaceutical development of proprietary drug delivery technologies for numerous indications using small molecules, biological, and botanical products to treat unmet medical needs. 

The Company has in-licensed BiPhasix™ Transdermal Drug Delivery platform technology for the delivery and commercialization of Cannabinoids, Cannabidiol (CBD), and Tetrahydrocannabinol (THC) based products, for human and animal use. 

Pivot Pharmaceuticals' potential CBD pharmaceutical pipeline includes PVT-011, PVT-0I2, PVT-013, and PVT-014. Pivot's subsidiary, Pivot Green Stream, centers on the research and development (R&D) of cannabinoid based nutraceuticals and pharmaceuticals. Pivot Green Stream’s initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005) and psoriasis (PGS-N007). It will look to register these as Natural Health Products (NHPs) for consumers.

Last week, Pivot Pharmaceuticals announced that it signed a Definitive Agreement with Altum Pharmaceuticals, Inc., to acquire the worldwide rights to  BiPhasix™ Transdermal Drug Delivery technology for the development and commercialization of Cannabinoids, Cannabidiol (CBD) and Tetrahydrocannabinol (THC) products.

BiPhasix™ pharmaceutical platform technology has been tested in Food and Drug Administration (FDA) and EMA approved trials in humans. The transaction includes U.S. Provisional Patent 16147-2 (138057) – “BiPhasix™ Cannabinoid Delivery”. 

BiPhasix™ can entrap and transport pharmaceutical products via the skin to realize therapeutic benefit in a broad array of indications. Studies have shown that BiPhasix™ can considerably enhance the bioavailability of numerous drugs, leading to improved clinical outcomes. The proprietary technology can also serve as an alternative dosage form to injectables through providing less invasive routes of administration, including dermal, transdermal, and nasal, vaginal, ocular, and rectal. 

Pivot Pharmaceuticals, Inc. (PVOTF), closed Monday's trading session at $0.13, up 23.81%, on 30,000 volume with 2 trades. The average volume for the last 60 days is 8,465 and the stock's 52-week low/high is $0.02/$0.15.

MGT Capital Investments, Inc. (MGTI)

OTC Markets and InvestorsHub reported on MGT Capital Investments, Inc. (MGTI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MGT Capital Investments, Inc. ranks as one of the largest United States-based Bitcoin miners. Its facility in WA State produces approximately 80 Bitcoins per month. MGT also continues to concentrate on an expansion model to grow its crypto assets materially.

Furthermore, the Company is developing a portfolio of cyber security technologies, creating advanced protection technologies for mobile and personal technology devices, and corporate networks. Industry pioneer John McAfee is the Company’s visionary leader in this corporate initiative. MGT Capital Investments is headquartered in Durham, North Carolina.

MGT’s first product is called Sentinel. This is an enterprise class network intrusion detector. At present, this product is in beta testing. The commercial release is anticipated by the end of this month.

In addition, the Company has entered into a joint venture (JV) with Nordic IT. This JV is to develop and market a mobile phone with extensive privacy and anti-hacking features. The tentative release date of the Privacy Phone is February 2018.

UAHC Ventures, LLC has partnered with MGT Capital Investments through providing a $2 million investment to the Company. The proceeds will be used by MGT to further expand and develop its Bitcoin mining operations. UAHC Ventures is a wholly-owned subsidiary of United American Healthcare Corporation (UAHC). UAHC Ventures was established to pursue strategic-investment opportunities in promising growth industries, including blockchain technologies and digital currency.

At the beginning of September,   MGT Capital Investments announced that it increased its purchase order with Bitmain Technologies for an additional 500 S9 Antminer Mining rigs. The expectation is that shipment will be in mid Q4 2017.

Following shipment and setup, and in combination with MGT’s current rigs in operation, the Company’s Bitcoin mining operations are expected to generate roughly $1.4 million in monthly revenue, assuming present pricing and difficulty rates.

Today, MGT Capital Investments announced that it was approved for up-listing and started trading effective today on the OTCQB Venture Market, operated by OTC Markets Group.

Mr. Robert Ladd, MGT Capital Investments’ President and Chief Executive Officer, stated, "We are pleased to be recognized with this move up to the OTCQB tier and will continue our high standards of transparency and financial reporting disclosure."

MGT Capital Investments, Inc. (MGTI), closed Monday's trading session at $2.70, up 20.54%, on 3,702,890 volume with 2,887 trades. The average volume for the last 60 days is 1,346,890 and the stock's 52-week low/high is $0.46/$4.26.

Umatrin Holding Limited (UMHL)

MarketWatch reported on Umatrin Holding Limited (UMHL), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Umatrin Holding Limited sells and trades in beauty, personal care, health, and wellness products, chiefly in Malaysia. The Company markets its products to end-users and dealers by way of an online channel and a retail store. U Matrin Worldwide Sdn Bhd (270883-X) is a subsidiary of Umatrin Holding Limited. U Matrin Worldwide has its headquarters in Kuala Lumpur. 

Umatrin has 10 years’ experience in Internet performance and security. The Company Incorporated in the state of Delaware on February 2, 2005. Umatrin lists on the OTC Markets Group’s OTCQB. 

Umatrin Holding originally incorporated to locate and negotiate with a targeted business entity for the combination of that target company with Umatrin Holding. To move forward with this vision, on January 6, 2016, Umatrin decided to acquire an operating company in Malaysia, named U Matrin Worldwide Sdn Bhd, into Umatrin Holding Limited. U Matrin Worldwide Sdn Bhd was awarded with a direct selling license by the Ministry of Domestic Trade and Consumer Affairs in Malaysia.   

Umatrin Holding operates in more than 25 countries and territories. The Company operates leading O2O (Online to Offline) marketplaces in the retail and wholesale trade. Umatrin provides technology and services to enable consumers, merchants, as well as other participants to conduct business in its cloud ecosystem. Umatrin Holding has greater than five years’ experience in managing e-commerce sites, brand marketing, product development, and financial security.

The Company’s products include (for Home Appliances) the Hyundai Waco Water Filter and the Hydrogen Alkaline Water Stick. For Healthcare, it offers the Nano Patch. This product is for maintaining a constant level of nutrients in the blood. 

In addition, Umatrin offers Soyme for preventing heart diseases and anti-aging effects, enhancing blood circulation, and reducing the body's cholesterol levels. Furthermore, the Company provides Sophielicous, an anti-aging supplement to enhance the longevity of skin cells; nano anti-aging face serum, nano eye contour serum, nano collagen face serum, nano whitening face serum, and nano vibration serum pen. 

Umatrin is employing advanced network technology and a strong management system that creates unlimited business brand space. Umatrin continuously introduces new products and combined O2O internet business model and career opportunities that do not necessitate large sums of operating cost. Umatrin has its Akero Secret product. Akero Secret is developed with 100 percent natural botanical active ingredients. It is a beauty product for clean and clear skin.

Moreover, Umatrin has its alkaline water system. The Company’s products include Unibersih. This is an herbal essence used for the treatment of constipation, pigmentation, overweightness, bad breath, unsound sleep, lack of physical strength, indigestion, abdominal swelling, dry and pale skin, poor immune system, and more. 

Umatrin Holding Limited (UMHL), closed Monday's trading session at $0.06, up 20.00%, on 5,500 volume with 4 trades. The average volume for the last 60 days is 15,079 and the stock's 52-week low/high is $0.0002/$0.21.

Medicine Man Technologies, Inc. (MDCL)

The Street, MarketWatch, Marketwired, CFN Media Group, and Stockhouse reported on Medicine Man Technologies, Inc. (MDCL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medicine Man Technologies, Inc. represents and licenses the cultivation and dispensary Intellectual Property (IP) of Medicine Man - a well-respected Tier III operator in Colorado. Medicine Man Technologies provides cultivation consulting services for cannabis growing technologies and methodologies. The Company is one of the nation’s top cannabis brand development and consulting enterprises.  Established in 2014, Medicine Man has its headquarters in Denver, Colorado. 

Medicine Man works closely with industry-leading extraction partners. These partners provide the required licensing service support and formulations to help customers with their planned deployment of a successful processing facility.

The Company is centering on working with clients to use its experience, technology, and training to help secure a license in states with newly emerging regulations. In addition, it is focusing on deploying its highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminating the liability of single grower dependence. 

Medicine Man is also continuing the expansion of its Brands Warehouse concept.  Additionally, the Company engages in retail operations of cannabis products. It also provides general business and referral management for other related service providers for its customers. It cultivates and sells via its parent company Medicine Man Denver, the largest cultivation/retail facility in Colorado. 

Medicine Man’s risk-averse cannabis cultivation technology delivers consistent, high quality, high yield production within a clean-room style environment. The Company’s state-of-the art dispensary model ensures patients and consumers have safe and secure access to an array of medical and/or recreational cannabis products.

Recently, Medicine Man Technologies announced the definitive agreement to acquire Denver Consulting Group, LLC was executed by the parties on July 21, 2017. This acquisition became effective on July 24th upon the filing of applicable documents with the Colorado Secretary of State. Denver Consulting Group has offices in Denver, Colorado, and Portland, Oregon.

Mr. Brett Roper, Medicine Man Technologies’ Chief Executive Officer and Co-Founder stated, “We are encouraged by the level of interest the ownership of the Denver Consulting Group has expressed in our forward planning, especially in our Cultivation MAX and Success Nutrient lines of business which we are expanding nationally. We believe that they will play a valuable role in our expansion and we are excited about the growth opportunities this consolidation will provide to our evolution as a Brands Warehouse.” 

Medicine Man Technologies, Inc. (MDCL), closed Monday's trading session at $1.04, up 0.97%, on 44,343 volume with 62 trades. The average volume for the last 60 days is 19,592 and the stock's 52-week low/high is $1.00/$5.00.

AmpliTech Group, Inc. (AMPG)

Penny Stock Gainers, RockingPennyStocks, BestStocksDaily, Wallstreetbuzz, AllPennyStocks, SmallCapVoice, PennyStocks24, Information Solutions Group, Pumps and Dumps, Trading Wall St, fusionspicks, Jet-Life Penny Stocks, OTCMagic, Ascending Stocks, HoleinOneStocks.net, HotStockProfits, and Fortune Penny Stocks reported earlier on AmpliTech Group, Inc. (AMPG), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF Low Noise Amplifiers (LNA) and Power Amplifiers (PA). These are for the domestic and international, SATCOM, Space, and Military markets. Also, the Company provides consulting services to help with any microwave components or systems design problems. AmpliTech sells its products via sales representatives and distributors in North America, Europe, and Asia. AmpliTech Group has its corporate office in Bohemia, New York.

Mr. Fawad Maqbool founded AmpliTech Group to fill the need for high quality, reliable, state-of-the-art, RF components at an affordable cost, with speedy deliveries and trouble-free customer service. Mr. Maqbool has more than 20 years of experience in the design of microwave amplifiers and components.  

AmpliTech’s designs encompass the frequency spectrum from 50 kHz to 40 GHz - eventually providing designs up to 100 GHz. The Company can provide complex, custom solutions for almost any custom requirements presented to it. It can provide contract assembly of customers' own designs.      

AmpliTech provides its customers with consulting services for their system development. Moreover, it provides technical assistance in integration and packaging technologies and microwave sub-systems and amplifier related sub-assemblies. 

AmpliTech employs the most up-to-date CAD microwave simulation technology to design and develop from concept to final manufacture of a deliverable product with premier accuracy. AmpliTech expects to release new products targeted at the wireless and satellite markets that will provide advanced technology and performance.

Recently, Amplitech Group announced that it entered into a Joint Venture (JV) Agreement with Trusted Networks, Inc. (TN). TN is a New York, New York based private company with facilities in Colorado Springs and Nashua, New Hampshire.

The focus of this JV is to develop an affordable mixed signal chipset, which can be used at server/router level and also in mobile PDA applications to provide secure and encrypted communication with the aim of preventing hacking and cyber-attacks.

The JV will leverage AmpliTech's industry leadership and experience in RF/Microwave LNA technology and TN's Cyber-security Protocol technology to eliminate the extensive occurrence of corporate and individual cyber-attacks.

AmpliTech Group (AMPG) Chief Executive Officer, Mr. Fawad Maqbool, stated, "We are excited to be part of what we think is a great partnership that brings together the best of both worlds to attack a problem that has found its way into mainstream cyber technology and our everyday way of life. As the use of information technology increases exponentially, the need for the type of solution this joint venture will provide is readily apparent. I am confident that it will position AMPG for increased revenue and market leadership in the not so distant future."

AmpliTech Group, Inc. (AMPG), closed Monday's trading session at $0.0406, down 6.67%, on 80,500 volume with 7 trades. The average volume for the last 60 days is 72,949 and the stock's 52-week low/high is $0.0391/$0.11.

graphic

The QualityStocks
Company Corner

graphic
graphic

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.7196, up 2.80%, on 306,357 volume with 200 trades. The stock’s average daily volume over the past 60 days is 101,353 and its 52-week low/high is $0.6171/$0.90.

ABcann Global Corporation (TSX-V:ABCN) (“ABcann” or the “Company”) is pleased to announce that it has received total proceeds of $11,895,298 from the exercise of an aggregate of 19,185,965 warrants since the closing of the Company’s acquisition of ABcann Medicinals Inc. (“ABcann Medicinals”) on April 28, 2017. These warrants, each of which was exercised into one ABcann common share, expired on September 9, 2017. They were originally issued under private placements completed by ABcann Medicinals in 2014 and 2015. After giving effect to the exercise of the warrants, ABcann’s current cash position stands at approximately $45 million, providing the Company with the capital necessary to expand its production.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global Receives $11.9 Million from Exercise of Warrants

ABcann Global Appoints Barry Fishman as Chief Executive Officer

ABcann Releases High Level CBD Product and Launches Initial Oils Strategy

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.57, off by 4.68%, on 66,652 volume with 66 trades. The stock’s average daily volume over the past 60 days is 67,805 and its 52-week low/high is $0.315/$2.75.

ChineseInvestors.com, Inc. (OTCQB: CIIX) ("CIIX" or the "Company"), the premier financial information website for Chinese-speaking investors, today announces that its wholly owned foreign enterprise, CBD Biotechnology Co. Ltd., has completed the filing process with the China Food & Drug Administration ("CFDA") for its first line of non-industrial hemp-infused skin care products. The Company expects to launch the CBD Magic Hemp Series skin care line in October positioning CBD Biotechnology as a leader in what it believes to be an untapped segment of China's skin care industry. 

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

ChineseInvestors.com, Inc.'s Wholly Owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Completes the Record Filing Process with the China FDA, Expects to Launch its Hemp Infused Skin Care Line in October

NetworkNewsWire Announces Publication on Cannabis Investment Options

ChineseInvestors.com, Inc. Announces Annual Financial Results, Posts 76% YoY Increase in Revenues, and Comments on Recent Stock Price Volatility as it May Relate to Recent News in the Digital Currency Industry

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0209, up 4.19%, on 2,614,633 volume with 70 trades. The stock’s average daily volume over the past 60 days is 2,163,052, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (OTC PINK: GOHE) ("Global") is pleased to announce that executive management members of its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company") successfully represented the Company this past week at the 4th annual Cannabis World Congress & Business Exposition held in Los Angeles, CA.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

MoneyTrac Technology, Inc. Establishes Key Industry Connections Through Participation in the 4th Annual Cannabis World Congress & Business Exposition in Los Angeles, CA

Global Payout's Moneytrac Technology Inc. Signs LOI with Renowned Marijuana Technology Company, BlazeNow, Inc.

Global Payout, Inc. Begins Company Audit with Intent of Filing Form 10-K and Becoming Fully Reporting Within 60 Days

Greenkraft, Inc. (GKIT)

The QualityStocks Daily Newsletter would like to spotlight Greenkraft, Inc. (GKIT). Today, Greenkraft, Inc. closed trading at $0.105, up 29.63%, on 27,301 volume with 7 trade. The stock’s average daily volume over the past 60 days is 11,705 and its 52-week low/high is $0.019/$0.20.

Greenkraft, Inc. (GKIT) is a nationally recognized company specializing in the production of alternative fuel automotive products, including engines and commercial trucks. Located in Santa Ana, California, the company's mission is to provide clean, green, energy efficient automotive products that have a price advantage coupled with unparalleled American performance. Established in 2008, Greenkraft, Inc. serves the commercial truck market powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7.

Greenkraft's new line of trucks, known as the G3 and G4, will accommodate weights of 26,000 lbs. and 33,000 lbs., respectively. George Gemayel, CEO of Greenkraft, Inc., said the demand for larger trucks that run on alternative fuels continues to increase.

"Greenkraft is going to revolutionize the trucking industry with these new 26,000 and 33,000 lbs. trucks that run on CNG and PROPANE fuel," Gemayel states in a press release. "The only way we can meet increased demand for Greenkraft products is to expand our current factory. This expansion is one of many factors that will substantially increase the Company's revenue in 2017."

Greenkraft produces a cab forward design for its commercial trucks, which allows the passenger area to be much larger than in other similar sized vehicles. Several tank capacity options exist, making it easy to select the most efficient model for a client's specific needs. Greenkraft is one of the only companies in the world to offer a refrigeration option with an alternative fuel truck – an essential, must-have option for many businesses.

Greenkraft trucks, considered among the best performing in the heavy-duty market, are used in a variety of industries and in some of the nation's largest cities. The company also offers a line of trucks designed to run with a package from Allison Transmission Holdings, Inc. (NYSE: ALSN), which gives clients the option of purchasing a fully automatic transmission vehicle. This option expands the size of the driver pool since fully automatic shifting reduces driver fatigue, contributes to solving the issue of driver retention, and it is easy to use.

CNG and LPG conversion systems made by Greenkraft are available for several major automobile brands including Ford, GM and Isuzu/GM. Installation, service, parts and warranty are all available through Greenkraft facilities and its partners. Disclaimer

Greenkraft, Inc. Blog

Greenkraft, Inc. News:

Greenkraft, Inc. (GKIT) Making Itself Available to the Entirety of the United States

Greenkraft, Inc. (OTCQB: GKIT) Now Offering an Allison Transmission for Their Alternative Fuel Trucks

Greenkraft, Inc. Publishes 500% Revenue Increase and Continues Positive Momentum by Achieving Near Zero Emissions in Their Trucks

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.40, up 1.27%, on 102,456 volume with 49 trades. The stock’s average daily volume over the past 60 days is 84,548 and its 52-week low/high is $0.11/$0.699.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria's TurboCBD

NetworkNewsWire Announces Publication Highlighting Companies Taking Innovative Strides in the Tobacco Industry

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

PennyStockProphet
(HIVE.V) +220.00%

2.

Buzz Stocks
(ITUS) +85.51%

3.

MarketBeat
(GIGL) +37.34%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251